Apparent acetaminophen toxicity in a patient with transaldolase deficiency

Jasmine Lee-Barber, Taylor E. English, Jacquelyn F. Britton, Nara Sobreira, Jason Goldstein, David Valle, Hans Tomas Bjornsson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Transaldolase deficiency (MIM#: 606003) is a rare autosomal recessive defect in the pentose phosphate pathway. Affected individuals are at risk for progressive liver failure and hepatocarcinoma. In the transaldolase-deficient mouse model (Taldo1−/−), these hepatic complications are accentuated by oxidative stress related to acetaminophen administration. We report a 13-month-old transaldolase-deficient male who developed mild liver failure after receiving standard doses of acetaminophen during a febrile respiratory syncytial virus infection. He was admitted for respiratory distress with neutropenia and thrombocytopenia, but developed an enlarged nodular liver with accompanying splenomegaly and rising alpha-fetoprotein which peaked 2 weeks after acetaminophen exposure. Whole exome sequencing revealed compound heterozygous variants c.512_514delCCT (p.Ser171del) and c.931G > T (p.Gly311Trp) in TALDO1 (HGNC:11559), which encodes transaldolase (EC 2.2.1.2), a key enzyme in ribose metabolism. Urine polyols and plasma metabolomics confirmed the diagnosis of transaldolase deficiency. Studies on the Taldo1−/− mouse model demonstrate acetamino-phen-induced liver failure can be prevented by administration of the antioxidant N-acetylcysteine. Moreover, a published report showed treatment of a transaldolase-deficient patient with N-acetylcysteine was associated with a decrease in alpha-fetoprotein levels. After discontinuation of acetaminophen and prior to initiation of N-acetylcysteine treatment, our patient demonstrated resolving alpha-fetoprotein levels suggesting acetaminophen incited the liver failure. Conclusion: Our observations support the conclusion from mouse model studies that transaldolase-deficient patients are uniquely sensitive to acetaminophen and should avoid this antipyretic. Recognition of this individualized toxicity and avoidance of acetaminophen are essential for management of these patients.

Original languageEnglish (US)
Title of host publicationJIMD Reports
PublisherSpringer
Pages9-15
Number of pages7
DOIs
StatePublished - Jan 1 2019

Publication series

NameJIMD Reports
Volume44
ISSN (Print)2192-8304
ISSN (Electronic)2192-8312

Fingerprint

Transaldolase
Acetaminophen
Toxicity
Liver
Liver Failure
alpha-Fetoproteins
Acetylcysteine
Patient treatment
Exome
Pentoses
Respiratory Syncytial Virus Infections
Pentose Phosphate Pathway
Antipyretics
Oxidative stress
Metabolomics
Ribose
Hepatomegaly
Splenomegaly
Transaldolase Deficiency
Neutropenia

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)

Cite this

Lee-Barber, J., English, T. E., Britton, J. F., Sobreira, N., Goldstein, J., Valle, D., & Bjornsson, H. T. (2019). Apparent acetaminophen toxicity in a patient with transaldolase deficiency. In JIMD Reports (pp. 9-15). (JIMD Reports; Vol. 44). Springer. https://doi.org/10.1007/8904_2018_116

Apparent acetaminophen toxicity in a patient with transaldolase deficiency. / Lee-Barber, Jasmine; English, Taylor E.; Britton, Jacquelyn F.; Sobreira, Nara; Goldstein, Jason; Valle, David; Bjornsson, Hans Tomas.

JIMD Reports. Springer, 2019. p. 9-15 (JIMD Reports; Vol. 44).

Research output: Chapter in Book/Report/Conference proceedingChapter

Lee-Barber, J, English, TE, Britton, JF, Sobreira, N, Goldstein, J, Valle, D & Bjornsson, HT 2019, Apparent acetaminophen toxicity in a patient with transaldolase deficiency. in JIMD Reports. JIMD Reports, vol. 44, Springer, pp. 9-15. https://doi.org/10.1007/8904_2018_116
Lee-Barber J, English TE, Britton JF, Sobreira N, Goldstein J, Valle D et al. Apparent acetaminophen toxicity in a patient with transaldolase deficiency. In JIMD Reports. Springer. 2019. p. 9-15. (JIMD Reports). https://doi.org/10.1007/8904_2018_116
Lee-Barber, Jasmine ; English, Taylor E. ; Britton, Jacquelyn F. ; Sobreira, Nara ; Goldstein, Jason ; Valle, David ; Bjornsson, Hans Tomas. / Apparent acetaminophen toxicity in a patient with transaldolase deficiency. JIMD Reports. Springer, 2019. pp. 9-15 (JIMD Reports).
@inbook{ab7529ef9ead4f1d8d1694ed36e8ba4c,
title = "Apparent acetaminophen toxicity in a patient with transaldolase deficiency",
abstract = "Transaldolase deficiency (MIM#: 606003) is a rare autosomal recessive defect in the pentose phosphate pathway. Affected individuals are at risk for progressive liver failure and hepatocarcinoma. In the transaldolase-deficient mouse model (Taldo1−/−), these hepatic complications are accentuated by oxidative stress related to acetaminophen administration. We report a 13-month-old transaldolase-deficient male who developed mild liver failure after receiving standard doses of acetaminophen during a febrile respiratory syncytial virus infection. He was admitted for respiratory distress with neutropenia and thrombocytopenia, but developed an enlarged nodular liver with accompanying splenomegaly and rising alpha-fetoprotein which peaked 2 weeks after acetaminophen exposure. Whole exome sequencing revealed compound heterozygous variants c.512_514delCCT (p.Ser171del) and c.931G > T (p.Gly311Trp) in TALDO1 (HGNC:11559), which encodes transaldolase (EC 2.2.1.2), a key enzyme in ribose metabolism. Urine polyols and plasma metabolomics confirmed the diagnosis of transaldolase deficiency. Studies on the Taldo1−/− mouse model demonstrate acetamino-phen-induced liver failure can be prevented by administration of the antioxidant N-acetylcysteine. Moreover, a published report showed treatment of a transaldolase-deficient patient with N-acetylcysteine was associated with a decrease in alpha-fetoprotein levels. After discontinuation of acetaminophen and prior to initiation of N-acetylcysteine treatment, our patient demonstrated resolving alpha-fetoprotein levels suggesting acetaminophen incited the liver failure. Conclusion: Our observations support the conclusion from mouse model studies that transaldolase-deficient patients are uniquely sensitive to acetaminophen and should avoid this antipyretic. Recognition of this individualized toxicity and avoidance of acetaminophen are essential for management of these patients.",
author = "Jasmine Lee-Barber and English, {Taylor E.} and Britton, {Jacquelyn F.} and Nara Sobreira and Jason Goldstein and David Valle and Bjornsson, {Hans Tomas}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/8904_2018_116",
language = "English (US)",
series = "JIMD Reports",
publisher = "Springer",
pages = "9--15",
booktitle = "JIMD Reports",

}

TY - CHAP

T1 - Apparent acetaminophen toxicity in a patient with transaldolase deficiency

AU - Lee-Barber, Jasmine

AU - English, Taylor E.

AU - Britton, Jacquelyn F.

AU - Sobreira, Nara

AU - Goldstein, Jason

AU - Valle, David

AU - Bjornsson, Hans Tomas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Transaldolase deficiency (MIM#: 606003) is a rare autosomal recessive defect in the pentose phosphate pathway. Affected individuals are at risk for progressive liver failure and hepatocarcinoma. In the transaldolase-deficient mouse model (Taldo1−/−), these hepatic complications are accentuated by oxidative stress related to acetaminophen administration. We report a 13-month-old transaldolase-deficient male who developed mild liver failure after receiving standard doses of acetaminophen during a febrile respiratory syncytial virus infection. He was admitted for respiratory distress with neutropenia and thrombocytopenia, but developed an enlarged nodular liver with accompanying splenomegaly and rising alpha-fetoprotein which peaked 2 weeks after acetaminophen exposure. Whole exome sequencing revealed compound heterozygous variants c.512_514delCCT (p.Ser171del) and c.931G > T (p.Gly311Trp) in TALDO1 (HGNC:11559), which encodes transaldolase (EC 2.2.1.2), a key enzyme in ribose metabolism. Urine polyols and plasma metabolomics confirmed the diagnosis of transaldolase deficiency. Studies on the Taldo1−/− mouse model demonstrate acetamino-phen-induced liver failure can be prevented by administration of the antioxidant N-acetylcysteine. Moreover, a published report showed treatment of a transaldolase-deficient patient with N-acetylcysteine was associated with a decrease in alpha-fetoprotein levels. After discontinuation of acetaminophen and prior to initiation of N-acetylcysteine treatment, our patient demonstrated resolving alpha-fetoprotein levels suggesting acetaminophen incited the liver failure. Conclusion: Our observations support the conclusion from mouse model studies that transaldolase-deficient patients are uniquely sensitive to acetaminophen and should avoid this antipyretic. Recognition of this individualized toxicity and avoidance of acetaminophen are essential for management of these patients.

AB - Transaldolase deficiency (MIM#: 606003) is a rare autosomal recessive defect in the pentose phosphate pathway. Affected individuals are at risk for progressive liver failure and hepatocarcinoma. In the transaldolase-deficient mouse model (Taldo1−/−), these hepatic complications are accentuated by oxidative stress related to acetaminophen administration. We report a 13-month-old transaldolase-deficient male who developed mild liver failure after receiving standard doses of acetaminophen during a febrile respiratory syncytial virus infection. He was admitted for respiratory distress with neutropenia and thrombocytopenia, but developed an enlarged nodular liver with accompanying splenomegaly and rising alpha-fetoprotein which peaked 2 weeks after acetaminophen exposure. Whole exome sequencing revealed compound heterozygous variants c.512_514delCCT (p.Ser171del) and c.931G > T (p.Gly311Trp) in TALDO1 (HGNC:11559), which encodes transaldolase (EC 2.2.1.2), a key enzyme in ribose metabolism. Urine polyols and plasma metabolomics confirmed the diagnosis of transaldolase deficiency. Studies on the Taldo1−/− mouse model demonstrate acetamino-phen-induced liver failure can be prevented by administration of the antioxidant N-acetylcysteine. Moreover, a published report showed treatment of a transaldolase-deficient patient with N-acetylcysteine was associated with a decrease in alpha-fetoprotein levels. After discontinuation of acetaminophen and prior to initiation of N-acetylcysteine treatment, our patient demonstrated resolving alpha-fetoprotein levels suggesting acetaminophen incited the liver failure. Conclusion: Our observations support the conclusion from mouse model studies that transaldolase-deficient patients are uniquely sensitive to acetaminophen and should avoid this antipyretic. Recognition of this individualized toxicity and avoidance of acetaminophen are essential for management of these patients.

UR - http://www.scopus.com/inward/record.url?scp=85060805089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060805089&partnerID=8YFLogxK

U2 - 10.1007/8904_2018_116

DO - 10.1007/8904_2018_116

M3 - Chapter

C2 - 29923087

AN - SCOPUS:85060805089

T3 - JIMD Reports

SP - 9

EP - 15

BT - JIMD Reports

PB - Springer

ER -